SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) — Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be used to support the further clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
